title: Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids.
abstract: BACKGROUND
  GLCCI1 rs37972 has previously been associated with decreased lung function improvement upon treatment with inhaled corticosteroids (ICS) in asthmatics.
  
  
  OBJECTIVE
  To assess whether variation in rs37972 is associated with altered ICS efficacy in north European asthmatic children and young adults with a reported use of ICS.
  
  
  METHODS
  rs37972 was genotyped in three cohort studies of asthmatic children with a reported use of ICS. As an indicator for asthma exacerbations, asthma-related hospital visits and oral corticosteroid use were studied. Asthma control was assessed using a questionnaire.
  
  
  RESULTS
  rs37972 T allele was not significantly associated with an increased risk of oral corticosteroid use (summary odds ratio: 1.20; 95% CI: 0.99-1.45), an increased risk of asthma-related hospital visits (summary odds ratio: 1.07; 95% CI: 0.89-1.29), uncontrolled symptoms (summary odds ratio: 1.01; 95% CI: 0.75-1.36) or higher ICS dosages (summary β: 0.01, 95% CI: -0.06-0.08).
  
  
  CONCLUSIONS
  Variation in GLCCI1 rs37972 genotype does not seem to affect ICS efficacy in north European asthmatic children. Original submitted 26 November 2013; Revision submitted 13 February 2014.
authors.affiliation: Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, Utrecht, The Netherlands and Department of Respiratory Medicine & Laboratory for Translational Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands.
authors.forename: Susanne J H
authors.initials: SJ
authors.lastname: Vijverberg
authors.forename: Roger
authors.initials: R
authors.lastname: Tavendale
authors.forename: Maarten
authors.initials: M
authors.lastname: Leusink
authors.forename: Leo
authors.initials: L
authors.lastname: Koenderman
authors.forename: Jan A M
authors.initials: JA
authors.lastname: Raaijmakers
authors.forename: Dirkje S
authors.initials: DS
authors.lastname: Postma
authors.forename: Gerard H
authors.initials: GH
authors.lastname: Koppelman
authors.forename: Steve W
authors.initials: SW
authors.lastname: Turner
authors.forename: Somnath
authors.initials: S
authors.lastname: Mukhopadhyay
authors.forename: Colin N A
authors.initials: CN
authors.lastname: Palmer
authors.forename: Anke Hilse
authors.initials: AH
authors.lastname: Maitland-van der Zee
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000328:Adult; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage; D001249:Asthma / Q000188:drug therapy* / Q000235:genetics*; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D006801:Humans; D010372:Pediatrics; D010597:Pharmacogenetics / Q000379:methods; D011965:Receptors, Glucocorticoid / Q000235:genetics*; D044465:White People / Q000235:genetics*; D055815:Young Adult
chemical_list: D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents; C561807:GLCCI1 protein, human; D011965:Receptors, Glucocorticoid
keywords: GLCCI1; asthma; children; corticosteroids; exacerbations; rs37972